Machine learning algorithms performed no better than regression models for prognostication in traumatic brain injuryShow others and affiliations
Number of Authors: 2442020 (English)In: Journal of Clinical Epidemiology, ISSN 0895-4356, E-ISSN 1878-5921, Vol. 122, p. 95-107Article in journal (Refereed) Published
Abstract [en]
OBJECTIVE: We aimed to explore the added value of common machine learning (ML) algorithms for prediction of outcome for moderate and severe traumatic brain injury.
STUDY DESIGN AND SETTING: We performed logistic (LR), lasso, and ridge regression with key baseline predictors in the IMPACT-II database (15 studies, n=11,022). ML algorithms included support vector machines, random forests, gradient boosting machines, and artificial neural networks, and were trained using the same predictors. To assess generalizability of predictions, we performed internal, internal-external, and external validation on the recent CENTER-TBI study (patients with GCS<13, n = 1,554). Both calibration (calibration slope/intercept) and discrimination (AUC) was quantified.
RESULTS: In the IMPACT-II database, 3,332/11,022(30%) died and 5,233(48%) had unfavorable outcome (Glasgow Outcome Scale below 4). In the CENTER-TBI study, 348/1,554(29%) died and 651(54%) had unfavorable outcome. Discrimination and calibration varied widely between the studies, and less so between the studied algorithms. The mean AUC was 0.82 for mortality and 0.77 for unfavorable outcome in CENTER-TBI.
CONCLUSION: ML algorithms may not outperform traditional regression approaches in a low-dimensional setting for outcome prediction after moderate or severe TBI. Similar to regression-based prediction models, ML algorithms should be rigorously validated to ensure applicability to new populations.
Place, publisher, year, edition, pages
Elsevier, 2020. Vol. 122, p. 95-107
Keywords [en]
Cohort study, Data science, Machine learning, Prediction, Prognosis, Traumatic brain injury
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
URN: urn:nbn:se:oru:diva-81118DOI: 10.1016/j.jclinepi.2020.03.005ISI: 000538788700015PubMedID: 32201256Scopus ID: 2-s2.0-85082847791OAI: oai:DiVA.org:oru-81118DiVA, id: diva2:1423006
Funder
EU, FP7, Seventh Framework Programme, 602150
Note
Data used in preparation of this manuscript were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Union 7th Framework program (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), the OneMind (USA) and the Integra LifeSciences Corporation (USA). The funder had no role in the study design, enrollment, collection of data, writing, or publication decisions.
2020-04-122020-04-122021-02-04Bibliographically approved